EQUIPE LABELISÉE LIGUE CONTRE LE CANCER, INSERM U1111-CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UMR5308.
Blood. 2015 Aug 27;126(9):1052-3. doi: 10.1182/blood-2015-06-652040.
In this issue of Blood, Sugata et al report that vaccination against human T-cell leukemia virus type 1 (HTLV-1) basic leucine zipper (bZIP) factor (HBZ) could be used for immunotherapy in adult T-cell leukemia-lymphoma (ATL) patients.
在本期《Blood》中,Sugata 等人报告称,针对人 T 细胞白血病病毒 1(HTLV-1)碱性亮氨酸拉链(bZIP)因子(HBZ)的疫苗接种可用于成人 T 细胞白血病-淋巴瘤(ATL)患者的免疫治疗。